JP2016520077A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520077A5
JP2016520077A5 JP2016513459A JP2016513459A JP2016520077A5 JP 2016520077 A5 JP2016520077 A5 JP 2016520077A5 JP 2016513459 A JP2016513459 A JP 2016513459A JP 2016513459 A JP2016513459 A JP 2016513459A JP 2016520077 A5 JP2016520077 A5 JP 2016520077A5
Authority
JP
Japan
Prior art keywords
polypeptide
hcv
hcv genotype
genotype
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016513459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520077A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/001972 external-priority patent/WO2015132619A1/en
Publication of JP2016520077A publication Critical patent/JP2016520077A/ja
Publication of JP2016520077A5 publication Critical patent/JP2016520077A5/ja
Withdrawn legal-status Critical Current

Links

JP2016513459A 2013-05-15 2014-05-15 E1e2hcvワクチン及び使用方法 Withdrawn JP2016520077A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361823712P 2013-05-15 2013-05-15
US61/823,712 2013-05-15
US201361887229P 2013-10-04 2013-10-04
US61/887,229 2013-10-04
PCT/IB2014/001972 WO2015132619A1 (en) 2013-05-15 2014-05-15 E1e2 hcv vaccines and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019087976A Division JP2019142962A (ja) 2013-05-15 2019-05-08 E1e2 hcvワクチン及び使用方法

Publications (2)

Publication Number Publication Date
JP2016520077A JP2016520077A (ja) 2016-07-11
JP2016520077A5 true JP2016520077A5 (https=) 2017-06-22

Family

ID=54054625

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016513459A Withdrawn JP2016520077A (ja) 2013-05-15 2014-05-15 E1e2hcvワクチン及び使用方法
JP2019087976A Withdrawn JP2019142962A (ja) 2013-05-15 2019-05-08 E1e2 hcvワクチン及び使用方法
JP2021001926A Pending JP2021059596A (ja) 2013-05-15 2021-01-08 E1e2 hcvワクチン及び使用方法
JP2022137454A Pending JP2022172244A (ja) 2013-05-15 2022-08-31 E1e2 hcvワクチン及び使用方法
JP2024130501A Pending JP2024156917A (ja) 2013-05-15 2024-08-07 E1e2 hcvワクチン及び使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019087976A Withdrawn JP2019142962A (ja) 2013-05-15 2019-05-08 E1e2 hcvワクチン及び使用方法
JP2021001926A Pending JP2021059596A (ja) 2013-05-15 2021-01-08 E1e2 hcvワクチン及び使用方法
JP2022137454A Pending JP2022172244A (ja) 2013-05-15 2022-08-31 E1e2 hcvワクチン及び使用方法
JP2024130501A Pending JP2024156917A (ja) 2013-05-15 2024-08-07 E1e2 hcvワクチン及び使用方法

Country Status (8)

Country Link
US (3) US20210145963A9 (https=)
EP (2) EP3689375A1 (https=)
JP (5) JP2016520077A (https=)
CN (2) CN105263517B (https=)
AU (3) AU2014385320B2 (https=)
CA (1) CA2909586C (https=)
CL (1) CL2015003333A1 (https=)
WO (1) WO2015132619A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4491735A3 (en) * 2015-10-08 2025-04-16 The Governors of the University of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
WO2018068132A1 (en) 2016-10-11 2018-04-19 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions comprising as an adjuvant a cyclic dinucleotide or an archaeosome and methods of use thereof
EP3765075A4 (en) * 2018-03-16 2021-12-08 The Governors of the University of Alberta HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHOD OF USING THEREOF
WO2025222304A1 (en) * 2024-04-26 2025-10-30 The Governors Of The University Of Alberta Hcv genotype3 e2 envelope protein for neutralizing infectivity of hcv strains

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
DE69841015D1 (de) 1997-05-06 2009-09-10 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
SK15762003A3 (sk) * 2001-06-29 2005-01-03 Chiron Corporation Kompozícia vakcíny HCV E1E2
US7348011B2 (en) * 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
US8603468B2 (en) * 2007-11-06 2013-12-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Neutralization of HCV
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
Filippelli et al. Hepatitis B vaccine by intradermal route in non responder patients: an update
van Riet et al. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design
JP2019151636A5 (https=)
JP2016520077A5 (https=)
HRP20201953T1 (hr) Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b
JP2016531144A5 (https=)
HRP20221263T1 (hr) Ciklički di-nukleotidni spojevi i postupci uporabe
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
JP2018523668A5 (https=)
RU2017137357A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
Romeli et al. Multi-epitope peptide-based and vaccinia-based universal influenza vaccine candidates subjected to clinical trials
JP2012526839A5 (https=)
JP2018505882A5 (https=)
JP2016508999A5 (https=)
JP2019531293A5 (https=)
FI3166615T3 (fi) Kelatoituja fosforotioaattinukleiinihappopolymeerejä käytettäväksi yhdistelmänä HBV-polymeraasin inhibiittorin kanssa hepatiitti B- ja hepatiitti D -virusinfektioiden hoitamiseksi
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
JP2017512194A5 (https=)
JP2017526689A5 (https=)
Bhandari et al. Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic
JP2013522231A5 (https=)
JP2019510064A5 (https=)
JP2019500379A5 (https=)
EA201892212A1 (ru) Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b